Expression of vascular endothelial growth factor (VEGF) in vulvar squamous cancer and VIN

Polish Journal of Pathology

Volumn 56, Issue 1, 2005, Pages 5-8

  Lewy Trenda, Iwona ^a,b   Wierzchniewska Ławska, Agnieszka ^a   Papierz, Wielisław ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Pathomorphology ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGENIC SUBSTRATE; DAKO DAB; DAKO STREPTAB COMPLEX; HRP DUET; KI 67 ANTIGEN; POLYCLONAL ANTIBODY; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CANCER GROWTH; CELL PROLIFERATION; CYTOPLASM; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MITOSIS RATE; PARACRINE SIGNALING; PRECANCER; PROTEIN EXPRESSION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; VULVA DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VULVAR NEOPLASMS;

EID: 19544394830     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bamberger ES, Perrett CW: Angiogenesis in benign, pre-malignant vulvar lesions. Anticancer Res 2002, 22, 3853-3865.
2. Bancher-Todesca D, Obermair A, Bilgi S, Kohlberger P, Kainz C, Breitenecker G, Leodolter S, Gitch G: Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 1997, 64, 496-500.
3. Ferrara N: Natural killer cells adhesion and tumor angiogenesis. Nature Med 1996, 2, 971-972.
4. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
5. Folkman J: Tumor angiogenesis: therapeutic complications. N Engl J Med 1971, 285, 1182-1186.
6. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumours. Ann Surg 1972, 175, 409-416.
7. Folkman J: Tumour angiogenesis factor. Cancer Res 1974, 34, 2109-2113.
8. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
9. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82, 4-6.
10. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 26, 1757-1763.
11. Folkman J: Tumor angiogenesis and tissue factors. Nature Med 1996, 2, 167-168.
12. Folkman J: Angiogenesis research: from laboratory to clinic. Forum (Geneva) 1999, 9(3 Supply 3), 59-62.
13. Folkman J: Incipient angiogenesis, J Natl Cancer Inst 2000, 92(2), 94-95.
14. Fox SB, Leek RD, Weekes MP et al: Quantisation and prognosis value of breast cancer angiogenesis: comparison of microvessel density. Chalky count and computer image analysis. J Pathol 1995, 177, 275-283
15. Fox SB: Tumor angiogenesis and prognosis. Histopathology 1997, 30, 294-301.
16. Gasparini G: Angiogenesis in preneoplastic and neoplastic lesions. Cancer J 1995, 8, 91-93.
17. Gibaldi M: Regulating angiogenesis: a new therapeutic strategy. J Clin Pharmac 1998, 38, 898-903.
18. Hennry TD: Therapeutic angiogenesis. BMJ 1999, 318, 1536-1539.
19. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21 (3), 505-515.
20. Kim K, Li B, Winer J, Armanini M, Gillett N, Philips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
21. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G: Increased expression of the vascular endothelial growth factors is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endoerinol Metab 2001, 86(2), 656-658.
22. Lewy-Trenda I: Nowotwory a angiogeneza. Pol Merk Lck 2002, 75, 347-350.
23. Lewy-Trenda I, Bleńkiewicz M; Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic thyroid lesions. Pol J Pathol 1999, 50, 129-138.
24. Lewy-Trenda I, Wierzchniewska-Ławska A: Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol 2002, 53, 59-65.
25. Radzikowski Cz, Opolski A, Wietrzyk J: Znaczenic angiogenezy w dynamiee wzrostu nowotworu. Post Hig Med Dośw 1998, 52, 553-576.
26. Szala S, Radzikowski Cz: Podłoże molekularne angiogenezy nowotworów. Nowotwory 1997, 47, 1-19.
27. Thompson WD, Li WW, Maraguodakis M: The clinical manipulation of angiogenesis: pathology, side effects, surprises, and opportunities with novel human therapies. J Pathol 1999, 187, 503-510.
28. Turley H, Scoot PAE, Watts VM, Bicknell R, Harris AL, Gatter KC: Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998, 186, 313-318.
29. Zagodziński W, Wallner G, Da̧browski A: Angiogenesis inhibitors. New anticancer strategy. Pol J Pharmacol 2000, 51, 455-462.
30. Zietz Ch, Rossle M, Haas Ch, Sendelhofert A, Hirschmann A, Sturz M, Lohrs U: MDM-2 oneoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998, 153, 1425-1433.